ATE286721T1 - Feste lösungskügelchen - Google Patents

Feste lösungskügelchen

Info

Publication number
ATE286721T1
ATE286721T1 AT98948383T AT98948383T ATE286721T1 AT E286721 T1 ATE286721 T1 AT E286721T1 AT 98948383 T AT98948383 T AT 98948383T AT 98948383 T AT98948383 T AT 98948383T AT E286721 T1 ATE286721 T1 AT E286721T1
Authority
AT
Austria
Prior art keywords
solid solution
surfactant
polyoxyethylene
hydrophobic
solution beads
Prior art date
Application number
AT98948383T
Other languages
English (en)
Inventor
Beth A Burnside
Guinness Charlotte M Mc
Edward M Rudnic
Richard A Couch
Xiaodi Guo
Alexander K Tustian
Original Assignee
Shire Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Lab Inc filed Critical Shire Lab Inc
Application granted granted Critical
Publication of ATE286721T1 publication Critical patent/ATE286721T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
AT98948383T 1997-09-19 1998-09-18 Feste lösungskügelchen ATE286721T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5940897P 1997-09-19 1997-09-19
PCT/US1998/019658 WO1999013864A2 (en) 1997-09-19 1998-09-18 Solid solution beadlet

Publications (1)

Publication Number Publication Date
ATE286721T1 true ATE286721T1 (de) 2005-01-15

Family

ID=22022768

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98948383T ATE286721T1 (de) 1997-09-19 1998-09-18 Feste lösungskügelchen

Country Status (9)

Country Link
US (1) US6692767B2 (de)
EP (1) EP1028712B1 (de)
JP (1) JP2002522354A (de)
AT (1) ATE286721T1 (de)
AU (1) AU9496798A (de)
CA (1) CA2302275C (de)
DE (1) DE69828635T2 (de)
ES (1) ES2236943T3 (de)
WO (1) WO1999013864A2 (de)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19819273A1 (de) * 1998-04-30 1999-11-11 Pharmatec International S Giul Pharmazeutische Ciclosporin-Formulierung mit verbesserten biopharmazeutischen Eigenschaften, erhöhter physikalischer Qualität und Stabilität sowie Verfahren zur Herstellung
US6117452A (en) * 1998-08-12 2000-09-12 Fuisz Technologies Ltd. Fatty ester combinations
AU2221600A (en) 1998-12-31 2000-07-31 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
AU2487300A (en) 1998-12-31 2000-07-31 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US7364752B1 (en) 1999-11-12 2008-04-29 Abbott Laboratories Solid dispersion pharamaceutical formulations
EP1175205B1 (de) * 1999-11-12 2006-06-14 Abbott Laboratories Feste dispersion mit ritonavir, fenofibrat oder griseofulvin
FR2805462B1 (fr) * 2000-02-24 2003-08-15 Therabel Res Nouvelle forme galenique orale a liberation prolongee de la molsidomine
BR0109602A (pt) * 2000-03-30 2004-06-29 Bristol Myers Squibb Co Glóbulos de liberação controlada contendo estavudina
DE10026698A1 (de) * 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
CN1255185C (zh) * 2001-05-03 2006-05-10 弗·哈夫曼-拉罗切有限公司 无定形甲磺酸奈非那韦的药物剂型
EP1411770A4 (de) 2001-07-05 2006-05-10 Chiron Corp Polynukleotide, die für antigene hiv-polypeptide des c-typs codieren, polypeptide und ihre verwendung
WO2003004001A1 (en) * 2001-07-06 2003-01-16 Lifecycle Pharma A/S Controlled agglomeration
US20030170614A1 (en) 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
FR2830447B1 (fr) * 2001-10-09 2004-04-16 Flamel Tech Sa Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
JP4698950B2 (ja) * 2002-04-09 2011-06-08 フラメル・テクノロジー アモキシシリンの改変された放出のための、マイクロカプセルの水性懸濁液形態での経口医薬品製剤
EP1492511B3 (de) 2002-04-09 2012-05-02 Flamel Technologies Orale wässrige suspension, mikrokapseln enthaltend, zur kontrollierten freisetzung von wirkstoffen
US7399488B2 (en) * 2002-07-05 2008-07-15 Collegium Pharmaceutical, Inc. Abuse-deterrent pharmaceutical compositions of opiods and other drugs
US8840928B2 (en) * 2002-07-05 2014-09-23 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
US8557291B2 (en) * 2002-07-05 2013-10-15 Collegium Pharmaceutical, Inc. Abuse-deterrent pharmaceutical compositions of opioids and other drugs
US10004729B2 (en) 2002-07-05 2018-06-26 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
US7988993B2 (en) 2002-12-09 2011-08-02 Andrx Pharmaceuticals, Inc. Oral controlled release dosage form
US7423004B2 (en) * 2003-01-31 2008-09-09 Smithkline Beecham Corporation Solid dispersion compositions
FR2852843B1 (fr) * 2003-03-24 2008-05-23 Karim Ioualalen Systeme galenique permettant le masquage du gout
US7318925B2 (en) * 2003-08-08 2008-01-15 Amgen Fremont, Inc. Methods of use for antibodies against parathyroid hormone
CN1838968A (zh) 2003-08-08 2006-09-27 艾伯吉尼斯公司 针对甲状旁腺激素(pth)之抗体和其用途
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
ES2600577T3 (es) * 2003-12-04 2017-02-09 Bend Research, Inc. Procedimiento de pulverización-solidificación que usa un extrusor para preparar composiciones en multipartículas de fármacos cristalinos
CA2547597A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate compositions with improved stability
US6984403B2 (en) * 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
KR100844628B1 (ko) * 2003-12-04 2008-07-07 화이자 프로덕츠 인크. 제약상 다입자의 제조 방법
WO2005053639A2 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Controlled release multiparticulates formed with dissolution enhancers
WO2005053652A1 (en) 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
EP1701702A1 (de) * 2003-12-04 2006-09-20 Pfizer Products Inc. Srüh-erstarrungsverfahren mit einem extrudierer zur herstellung von multiteilchenförmigen azitrhomycin-zusammensetzungen, die vorzugsweise ein poloxamer und ein glycerid enthalten
MXPA06005913A (es) * 2003-12-04 2006-06-27 Pfizer Prod Inc Formas de dosificacion de multiparticulas de azitromicina por procedimientos basados en liquidos.
ITMI20032399A1 (it) * 2003-12-09 2005-06-10 Zambon Spa Composizione farmaceutica contenente gabapentina.
WO2005079752A2 (en) * 2004-02-11 2005-09-01 Rubicon Research Private Limited Controlled release pharmaceutical compositions with improved bioavailability
GB2411355B (en) 2004-02-27 2006-02-22 Niche Generics Ltd Pharmaceutical composition
CA2916869A1 (en) 2004-06-12 2005-12-29 Jane C. Hirsh Abuse-deterrent drug formulations
EP1781257B1 (de) * 2004-08-13 2018-12-19 Emisphere Technologies, Inc. Pharmazeutische formulierungen mit mikropartikeln oder nanopartikeln eines zufuhrmittels
AR050615A1 (es) * 2004-08-27 2006-11-08 Novartis Ag Composiciones farmaceuticas para la administracion oral
US9132135B2 (en) * 2004-09-24 2015-09-15 University Of Maryland, Baltimore Method of treating organophosphorous poisoning
WO2006036686A2 (en) * 2004-09-24 2006-04-06 University Of Maryland, Baltimore Method of treating organophosphorous poisoning
FR2886150B1 (fr) * 2005-05-24 2007-08-24 Flamel Technologies Sa Forme pharmaceutique orale a base d'au moins un principe actif dont la solubilite varie en fonction des conditions de ph gastrique
AU2007335156A1 (en) * 2006-12-20 2008-06-26 Mylan Pharmaceuticals Ulc Pharmaceutical composition comprising a hot-melt granulated lubricant
US8974801B2 (en) * 2006-12-21 2015-03-10 Amphastar Pharmaceuticals Inc. Long term sustained release pharmaceutical composition containing aqueous suspension of bisphosphonate
FR2913884A1 (fr) * 2007-03-21 2008-09-26 Oralance Pharma Sa Systeme galenique hydrophobe non ionisable
EP2216015A4 (de) * 2007-11-02 2012-12-19 So Pharmaceutical Corp Komplex aus einem stoff mit geringer löslichkeit und einem tensid sowie verfahren zu seiner herstellung
US20100272861A1 (en) * 2007-12-05 2010-10-28 Thomas Lindemann Pulverous formulation of a fat-soluble active ingredient
WO2009153654A1 (en) * 2008-06-17 2009-12-23 Aurobindo Pharma Limited Solid dosage forms of antiretrovirals
ES2638815T5 (en) 2009-06-18 2025-06-26 Acerus Pharmaceuticals Usa Llc Safe desmopressin administration
EP2305742B1 (de) * 2009-10-01 2017-02-22 Symrise AG Sphärisches Kern-Schalen-Teilchen
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
BRPI0906820A2 (pt) * 2009-12-21 2013-07-30 Inst Presbiteriano Mackenzie matriz cerÂmica para incorporar fÁrmacos de liberaÇço controlada, comprimido, mÉtodo para obtenÇço da matriz cerÂmica e mÉtodo para produzir um comprimido
US10695431B2 (en) * 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US9271950B2 (en) 2010-10-29 2016-03-01 Infirst Healthcare Limited Compositions for treating chronic inflammation and inflammatory diseases
US9308213B2 (en) 2010-10-29 2016-04-12 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US9504664B2 (en) 2010-10-29 2016-11-29 Infirst Healthcare Limited Compositions and methods for treating severe pain
US11730709B2 (en) 2010-10-29 2023-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US8895537B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating cardiovascular diseases
US10695432B2 (en) * 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US11202831B2 (en) 2010-10-29 2021-12-21 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US11224659B2 (en) 2010-10-29 2022-01-18 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US9744132B2 (en) 2010-10-29 2017-08-29 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
CN107233569B (zh) 2011-10-25 2021-08-31 普罗西纳生物科学有限公司 抗体制剂和方法
CA2882730C (en) * 2012-08-22 2019-12-31 Arbor Pharmaceuticals, Llc Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof
CA2884270A1 (en) * 2012-09-18 2014-03-27 Mcneil-Ppc, Inc. Sustained release oral dosage forms comprising low melting propionic acid derivative particles
EP2897647A1 (de) * 2012-09-18 2015-07-29 McNeil-PPC, Inc. Pharmazeutische suspensionsformulierungen mit propionsäurederivatpartikeln mit niedrigem schmelzpunkt
US9675585B1 (en) 2016-03-24 2017-06-13 Ezra Pharma Extended release pharmaceutical formulations
US9687475B1 (en) 2016-03-24 2017-06-27 Ezra Pharma Llc Extended release pharmaceutical formulations with controlled impurity levels
US10285987B2 (en) 2017-04-28 2019-05-14 Amplipharm Pharmaceuticals, LLC Device and kit for dosing and dispensing non-liquid medicine
US9949967B2 (en) * 2016-04-28 2018-04-24 Amplipharm Pharmaceuticals, LLC Temozolomide powder formulation
WO2017189995A1 (en) * 2016-04-28 2017-11-02 Amplipharm Pharmaceuticals, LLC Temozolomide powder formulation
US9737530B1 (en) 2016-06-23 2017-08-22 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations
IT202000022126A1 (it) * 2020-09-18 2022-03-18 Nutrilinea S R L Procedimento per preparare formulazioni solide comprendenti un composto idrofobico disperdibili in un liquido a freddo e relative formulazioni solide

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3857933A (en) * 1969-10-17 1974-12-31 Hoechst Ag Process for the manufacture of a drug dosage form permitting controlled release of active ingredient
DE3421468A1 (de) * 1984-06-08 1985-12-19 Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim Lipidnanopellets als traegersystem fuer arzneimittel zur peroralen anwendung
IE904098A1 (en) 1989-11-13 1991-05-22 Nova Pharm Corp Lipospheres for controlled delivery of substances
JP3233402B2 (ja) 1989-11-13 2001-11-26 サイオス ノバ インコーポレイテッド 物質の制御送達用のリポスフェア
US5213810A (en) 1990-03-30 1993-05-25 American Cyanamid Company Stable compositions for parenteral administration and method of making same
SE9200858L (sv) * 1992-03-20 1993-09-21 Kabi Pharmacia Ab Metod för framställning av pellets med fördröjd frisättning
GB9224855D0 (en) 1992-11-27 1993-01-13 Smithkline Beecham Plc Pharmaceutical compositions
IL109770A0 (en) * 1993-05-29 1994-11-28 Smithkline Beecham Corp Thermal infusion process for preparing controlled release solid dosage forms of medicaments for oral administration and controlled release solid dosage forms of medicaments prepared thereby
US5430021A (en) 1994-03-18 1995-07-04 Pharmavene, Inc. Hydrophobic drug delivery systems
BE1009257A3 (nl) * 1995-03-21 1997-01-07 Universiteit Gent Lab Voor Far Farmaceutische matrix.

Also Published As

Publication number Publication date
WO1999013864A2 (en) 1999-03-25
CA2302275A1 (en) 1999-03-25
AU9496798A (en) 1999-04-05
US20010006650A1 (en) 2001-07-05
CA2302275C (en) 2009-12-08
DE69828635D1 (de) 2005-02-17
EP1028712B1 (de) 2005-01-12
US6692767B2 (en) 2004-02-17
WO1999013864A3 (en) 1999-08-12
EP1028712A2 (de) 2000-08-23
ES2236943T3 (es) 2005-07-16
DE69828635T2 (de) 2005-06-16
JP2002522354A (ja) 2002-07-23

Similar Documents

Publication Publication Date Title
DE69828635D1 (de) Feste lösungskügelchen
DK0839525T3 (da) Præparat med forlænget frigivelse
DE69819481D1 (de) Formulierungen von clarithromycin mit verlängerter wirkstoff-freisetzung
ATE251158T1 (de) Indolizin spal2 inhibitoren
ATE172359T1 (de) Kalt-sterilisermittel mit verlängerter aktivät
NO20000467D0 (no) Selvemulgerende formulering for lipofile forbindelser
FI964748A0 (fi) Huoneenlämpötilan sterilointiaine
FI970430A7 (fi) Atsa-asparaziinihappo analogeja 1-beta-interleukiinia muuttavan entsyy min inhibiittoreina
ATE41739T1 (de) Feste orale dosierungsformulierungen von kardiovaskularen heilmitteln mit konstanter freisetzungsgeschwindigkeit.
DK415689D0 (da) Farmaceutiske midler
DE60037726D1 (de) Carbonsäurederivate die die bindung von integrinen an ihre rezeptoren hemmen
FI890238A7 (fi) Aktiivista ainetta ohjelmoidusti vapauttavia galeenisia koostumuksia
AR015715A1 (es) Una composicion acondicionadora del cabello
EE04179B1 (et) Liitlipiidide kasutamine stabiliseerivate lisanditena seedeensüümide segude ravimpreparaatides
DK0703897T3 (da) Lipoxinforbindelser med forlænget halveringstid
PT697814E (pt) Formulacoes para verter que contem material polimerico glicois e gliceridos
IT1247945B (it) Agente avente attivita' batteriostatica e battericida
AR018969A1 (es) Composiciones blanqueadoras
FI970530A7 (fi) Koostumus aktiivisen aineen selektiiviseksi vapauttamiseksi
SE9700934D0 (sv) New formulation
ATE220547T1 (de) Arzneimittelformulierung mit kontrollierter wirkstofffreisetzung
ATE92752T1 (de) Spruehgetrocknete ibuprofen-zusammensetzungen.
NO992818L (no) Anvendelse av pereddiksyre i fiskeoppdrett
BR9705425A (pt) Preparações pulverulentas dispersíveis em água.
IT1232917B (it) Procedimento per la fabbricazione di microsfere tramite reticolazionedi proteine, microsfere cosi' ottenute e loro impieghi

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties